CDT Equity Registers 16.8M Shares for Resale, Reveals New J.J. Astor Terms and CEO Transition
CDT is trading near its 52-week low of $0.582 (6.0% above the low) on light trading volume (0.4× avg).
Summary
CDT Equity filed an S-1 registering 16.8M shares for resale — exceeding its current outstanding share count — while disclosing new J.J. Astor note terms, a Sarborg payment restructuring, and a CEO change.
Key Events · Financing and Capital Events · CDT
-
16.8M Shares Registered for Resale
The S-1 registers 16,825,644 shares for resale by selling stockholders, exceeding the 13,693,866 shares outstanding as of August 31, 2026. The company receives no proceeds; all sales benefit selling stockholders.
-
Sarborg Pre-Funded Warrants Exercised
12,131,122 shares were issued to Sarborg shareholders on August 28, 2026 upon cashless exercise of pre-funded warrants, representing the bulk of the registered shares. Corvus Capital (Andrew Regan's entity) received 5,436,540 of these shares.
-
J.J. Astor Note Terms Expanded
The filing registers 3,888,875 shares issuable to J.J. Astor under the Notes and Warrants, including 3,523,125 conversion shares and 365,750 warrant shares. A new $541,620 August note was issued and repaid in full by September 4, 2026, with 237,000 warrants at $1.69 exercise price.
-
Sarborg Payment Restructured
The August 31, 2026 amendment to the Sarborg Securities Purchase Agreement issued 650,000 shares to Sarborg and converted $1.75M of the $8M cash consideration into stock, with remaining cash payable at $150,000 monthly minimums and a final balance due May 31, 2027.
Analysis · CDT · Life Sciences
This S-1 registers 16,825,644 shares for resale — more than the 13,693,866 shares currently outstanding — creating a massive overhang on a stock already trading at $0.63. The filing also reveals new material terms: the August 31 J.J. Astor note ($541,620, repaid in full September 4) with 237,000 warrants at $1.69, the Sarborg amendment issuing 650,000 shares and restructuring $8M in cash consideration into monthly $150,000 payments, and the abrupt CEO transition from Andrew Regan to James Bligh on August 31. Against a backdrop of going-concern warnings, $747K cash, and a 1-for-10 reverse split in July, this registration formalizes the extreme dilution shareholders were asked to approve in the July/August proxy — and adds new financing terms that deepen the company's distress.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $485.2K. The 52-week trading range was $0.58 to $2,360.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.